[New European approval: Selinexor for triple class refractory multiple myeloma]

Bull Cancer. 2022 Jan;109(1):6-7. doi: 10.1016/j.bulcan.2021.06.018. Epub 2021 Nov 29.
[Article in French]
No abstract available

Keywords: Exportin 1 inhibitor; Inhibiteur exportine 1; Multiple myeloma; Myélome multiple; Selinexor; Sélinexor; Triple réfractaire; Triple-refractory.

Publication types

  • News

MeSH terms

  • ADP-ribosyl Cyclase 1 / immunology
  • Administration, Oral
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Clinical Trials, Phase II as Topic
  • Drug Resistance, Neoplasm*
  • Europe
  • Humans
  • Hydrazines / administration & dosage
  • Hydrazines / therapeutic use*
  • Immunomodulating Agents / therapeutic use
  • Membrane Glycoproteins / immunology
  • Multiple Myeloma / drug therapy*
  • Proteasome Inhibitors / therapeutic use
  • Recurrence
  • Triazoles / administration & dosage
  • Triazoles / therapeutic use*

Substances

  • Antibodies, Monoclonal, Humanized
  • Hydrazines
  • Immunomodulating Agents
  • Membrane Glycoproteins
  • Proteasome Inhibitors
  • Triazoles
  • selinexor
  • CD38 protein, human
  • ADP-ribosyl Cyclase 1